EBO2 (EBOO) Side Effects and Safety: What the Evidence Shows

EBO2 (also called EBOO) has a thin published safety record: a handful of small studies, a longer trail of clinic-reported experience, and a much larger body of research on ozone therapy generally that is relevant but not specific to this procedure. See the pillar guide for the mechanism and the evidence overview; this guide lays out what each safety-relevant source actually says, separates risks that come from the extracorporeal circuit itself from risks that come from ozone, and explains what “not FDA-approved” does and does not tell you about oversight.

What clinics report after sessions

Clinics that publish safety information about EBO2 describe similar, mild effects. A Pennsylvania clinic states that side effects are generally minimal but can include slight fatigue or localized bruising, and that staff monitor for and address any concerns immediately [1]. A California clinic describes mild side effects such as temporary fatigue or dizziness that typically resolve quickly [2]. These are self-reported, unaudited descriptions from businesses selling the procedure, not independent safety surveillance, so they should be read as a floor on what gets disclosed rather than a ceiling on what can happen. Neither clinic reports a serious complication, and neither describes a systematic process for tracking outcomes across all of its patients rather than the ones who happen to mention a problem at a follow-up visit. That distinction matters: an absence of reported serious events is not the same as a monitoring system built to catch them.

What the EBOO studies recorded

The largest controlled EBOO study, a trial of 28 patients with peripheral artery disease randomized to EBOO or intravenous prostacyclin, reported no side effects or complications during any of the 210 EBOO treatments administered across the trial [3]. That is a genuinely reassuring number on its face, but it comes from a single center, a specific patient population, and a research team with a direct interest in the technique’s reputation, and it long predates the wider range of conditions clinics market EBO2 for today. A single trial recording zero complications is not the same as an independent safety study powered to detect uncommon but serious events, which this trial was never designed to do.

Risks specific to an extracorporeal circuit

Any procedure that draws blood through a needle in one arm, circulates it outside the body, and returns it through a needle in the other arm carries a familiar set of access-related risks, whether the procedure is EBO2, apheresis, or dialysis. A Cleveland Clinic patient-education page on apheresis lists bleeding at the needle site, blood clots, infection, low blood pressure, and, occasionally, nerve damage causing numbness, tingling, or weakness from a misplaced needle or catheter [7]. A National Library of Medicine patient page on vascular access for hemodialysis describes similar concerns for anyone with an access point: watching for spreading redness, swelling, warmth, or pus, and for a fever, as signs of infection, and understanding that the access site can clot or narrow over time [8]. EBO2 uses temporary IV placement rather than the surgically created access covered in that page, so the risk profile is lower, but the same categories of problems, a bad stick, a line that clots, an infection at the site, apply in principle any time a needle stays in a vein for an extended period. EBO2 also involves a heparinized, extracorporeal circuit processing a substantial volume of blood outside the body during each session, which raises the same general questions dialysis and apheresis practice has long dealt with around anticoagulation and fluid balance: too little anticoagulant risks clotting in the tubing, and moving a large blood volume through an external circuit can, in theory, shift blood pressure or fluid balance in someone with an existing cardiovascular condition. None of the published EBOO reports describe this happening, but the underlying physical setup is the reason clinics screen for cardiovascular stability before treating anyone.

Risks specific to ozone

Separately from the circuit, ozone itself carries risks tied to how it interacts with blood and tissue. People with a significant deficiency in the enzyme G6PD are at risk of hemolysis, the breakdown of red blood cells, when exposed to oxidative stressors. A 1977 toxicology paper laid out the theoretical basis for this risk, modeling how G6PD-deficient red cells lose the enzyme’s protection against oxidation on exposure to ozone [9]. That paper models inhaled, ambient-level ozone exposure of the kind found in polluted urban air, not the brief, controlled contact between ozone and blood that EBO2 and other ozone therapies use, so it is not a direct study of the extracorporeal route. Clinics and practitioner sources nonetheless extrapolate from the same underlying enzyme deficiency to justify screening before any procedure that intentionally exposes blood to an oxidant. That is why a G6PD test appears repeatedly across clinic intake processes for ozone-based procedures, discussed further in the contraindications guide. Ozone is also why inhaling the gas is dangerous in a way that exposing blood to it briefly is not: the thin fluid layer lining the lungs has far less antioxidant capacity than the much larger volume of blood and plasma in the bloodstream, so the same gas that the body’s blood can neutralize in a controlled, brief exposure can injure lung tissue directly on inhalation [6]. This is also the reasoning behind keeping any ozone-blood circuit fully closed, since the gas is never meant to be breathed by anyone in the room.

Complications reported in the wider ozone-therapy literature

Looking past EBOO specifically, the broader ozone-therapy literature records both reassuring and concerning outcomes. A randomized trial that added ozonated autohemotherapy to standard treatment for insomnia and myofascial pain reported no adverse complications in either the treatment or control group [4]. Against that, a case report describes a patient using ozone autohemotherapy for hypertension and diabetes who developed sudden dizziness from hyperkalemia that progressed to sinus arrest, an arrhythmia that resolved once the therapy stopped and the hyperkalemia was treated [5]. A physician who helped popularize ozone therapy has also documented a death in 2001 linked to an intramuscular paravertebral injection technique, where too high an ozone concentration triggered a vagal reaction and cardiac arrest, along with a separate case of temporary bilateral vision loss following a cervical disc injection and a reported interaction in which patients taking ACE inhibitors experienced marked hypotension when ozonated blood was reinfused too quickly [6]. None of these reports involve EBOO’s closed, filtered circuit specifically, and most describe direct-injection techniques that differ from EBO2, but they establish that ozone therapy as a category has produced serious, sometimes fatal, complications when performed incorrectly or in inappropriate candidates. The pattern across these reports is not that ozone itself is unpredictable so much as that outcomes depend heavily on technique, concentration, and screening: the death linked to paravertebral injection followed an excessive concentration and volume delivered too quickly, and the sinus-arrest case involved a patient whose kidney disease already put her at risk for the hyperkalemia that triggered the arrhythmia. Neither report describes EBOO’s own equipment or protocol, but both are reasons that screening and practitioner training show up repeatedly across serious discussions of ozone therapy safety, EBO2 included.

Regulatory status and what it means for oversight

Ozone is not FDA-approved to treat any condition. Federal regulation describes it as a toxic gas with no known useful medical application in specific, adjunctive, or preventive therapy, a statement written primarily about ambient ozone exposure and ozone-generating devices rather than about EBO2 as a clinical procedure [10]. That means there is no FDA clearance process an EBO2 device or protocol has passed, and no federal agency inspects EBO2 clinics for procedural safety the way it would a regulated medical device or drug. Separately, the FTC has issued a warning letter to at least one ozone therapy clinic for marketing ozone-related services as an effective treatment for a specific disease without the substantiation the FTC Act requires [11]. That action targeted marketing claims, not the physical safety of the procedure itself, but it is a useful reminder that oversight of this field is fragmented: no single regulator evaluates whether EBO2 is safe or effective, and enforcement tends to arrive only after a clinic makes a claim regulators consider unsupported.

How to reduce risk

Because no regulator is checking these boxes for you, the questions fall to the patient. Ask who is performing the procedure and what their medical training is, since a source describing serious ozone-therapy complications specifically ties them to undertrained practitioners working without proper precautions [6]. Ask whether the filter and gas-exchange cartridge are single-use, which several clinics state as standard and which limits cross-contamination risk between patients. Ask what the clinic’s emergency protocol is if something goes wrong mid-session, since the same safety literature recommends that anyone performing ozone therapy be trained in basic life support and keep resuscitation equipment such as oxygen, a defibrillator, and emergency medications on hand [6]. A clinic that answers these questions readily and specifically is giving you more useful information than one that responds only with general reassurance. The clinic directory lists what individual clinics publish about their own pricing, services, and screening, which is a reasonable place to start comparing how forthcoming different clinics are before you call.

When to seek care

Contact the clinic or seek care promptly if you notice spreading redness, swelling, warmth, or drainage at either IV site, a fever, one arm becoming cold, numb, or noticeably weaker than the other, bleeding that does not stop with a few minutes of firm pressure, or chest pain, fainting, or severe dizziness during or shortly after a session [7][8]. These are the same warning signs relevant to any needle-based procedure involving an extracorporeal circuit, and clinics should be willing to tell you in advance how to reach them if one comes up after hours.

Bottom line

The published safety picture for EBO2 specifically is thin: mild, clinic-reported effects [1][2], one trial recording zero complications across 210 treatments [3], and no independent, large-scale safety study. The wider ozone therapy literature adds real, sometimes serious complications, mostly from techniques other than EBOO’s closed circuit [5][6], plus a clear, ozone-specific risk in people with G6PD deficiency [9]. Ozone therapy remains outside FDA approval for any condition [10], and the absence of reported harm in small studies should not be mistaken for evidence of safety at a larger scale.